

Final Appraisal Recommendation

Advice No: 1419 – November 2019

Dupilumab (Dupixent®) 200 mg and 300 mg solution for injection in pre-filled syringe, 200 mg solution for injection in pre-filled pen

Limited submission by Sanofi-Aventis

Recommendation of AWMSG

Dupilumab (Dupixent®) is recommended as an option for restricted use within NHS Wales.

Dupilumab (Dupixent®) is licensed for the treatment of moderate-to-severe atopic dermatitis in adolescents ≥ 12 to < 18 years who are candidates for systemic therapy.

Dupilumab (Dupixent®) is restricted for the treatment of moderate-to-severe atopic dermatitis in adolescents ≥ 12 to < 18 years who are candidates for systemic therapy, only if the disease has not responded to at least one other systemic therapy, or these are contraindicated or not tolerated.

Dupilumab (Dupixent®) is not recommended for use within NHS Wales outside of this subpopulation.

This recommendation applies only in circumstances where the approved Patient Access Scheme (PAS) is utilised or where the list/contract price is equivalent or lower than the PAS price.

Additional notes:

- Please refer to the Summary of Product Characteristics for the full licensed indication.
- Dupilumab (Dupixent®) 200 mg solution for injection in pre-filled pen is not currently marketed in the UK.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 4089), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 1419:
Dupilumab (Dupixent®) 200 mg and 300 mg solution for injection in pre-filled syringe, 200 mg solution for injection in pre-filled pen. November 2019.